Microreviews
Coping with the calcium overload caused by cell injury: ER to the rescue
Goutam Chandra1,2, Davi A. G. Mázala1,3 and Jyoti K. Jaiswal1,4
It was nearly a century ago that Lewis Victor Heilbrunn identified the requirement of extracellular Ca2+ for what he termed as ‘surface precipitation reaction‘, a process that allows the cytoplasm
Inhibitory DAMPs in immunogenic cell death and its clinical implications
Kazukuni Hayashi1,2, Fotis Nikolos3 and Keith S. Chan1,3
– [table id=388/] INHIBITORY DAMP OR INHIBITORY DAMPS? How are immunostimulatory DAMPs shut off? Under normal physiological conditions, the co-stimulatory molecules, CD80/86, on antigen presenting cells bind to the co-activating
The OFD1 protein is a novel player in selective autophagy: another tile to the cilia/autophagy puzzle
Manuela Morleo1 and Brunella Franco1,2
Autophagy is an evolutionary conserved and highly regulated cellular degradation pathway which entails the engulfment of cellular components into double-membrane vesicles, called autophagosomes, which then fuse with lysosomes to degrade
Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance
Beatrice Thier1,2 and Annette Paschen1,2
In recent years, therapy with immune modulating antibodies, termed immune checkpoint blockade (ICB), has revolutionized the treatment of advanced metastatic melanoma, yielding long-lasting clinical responses in a subgroup of patients. But despite this remarkable progress, resistance to therapy represents a major clinical challenge. ICB efficacy is critically dependent on cytotoxic CD8+ T cells targeting tumor cells in an HLA class I (HLA-I) antigen-dependent manner. Transcriptional suppression of the HLA-I antigen processing and presentation machinery (HLA-I APM) in melanoma cells leads to HLA-I-low/-negative tumor cell phenotypes escaping CD8+ T cell recognition and contributing to ICB resistance. In general, HLA-I-low/-negative tumor cells can be re-sensitized to T cells by interferons (IFN), augmenting HLA-I APM expression. However, this mechanism fails when melanoma cells acquire resistance to IFN, which recently turned out as a key resistance mechanism in (...)
To promote or inhibit glioma progression, that is the question for IL-33
Stephen M. Robbins1 and Donna L. Senger1
Glioblastoma represents one of the most fatal of human cancers. Although there has been progress in the treatment of glioblastoma as a result of a treatment regimen that combines maximal
TLR4: the fall guy in sepsis?
Joseph Menassa1, Christina Nedeva1, Corey Pollock1 and Hamsa Puthalakath1
WHOLE GENOME CRISPR SCREEN AND THE IDENTIFICATION OF Treml4 We reasoned that if immune cells undergo apoptosis during sepsis, ablation of the gene responsible for this in a sub-population should